Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/06/2023

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 648 publications

Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer.

Condition: Triple-Negative/Her2( +) Breast Cancer, Multiple Myeloma, and Non-Small-Cell Lung Cancer
Journal: Journal of the Egyptian National Cancer Institute
Treatment Used: Combination Immunotherapy and Chemotherapy
Published: January 01, 2023

Next-Generation Chimeric Antigen Receptor T-cells.

Condition: B-Cell Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)
Journal: Hematology/oncology and stem cell therapy
Treatment Used: CAR T-Cell Therapy
Published: December 20, 2022

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.

Condition: Multiple Myeloma
Journal: Journal of medical case reports
Treatment Used: LCAR-B38M Chimeric Antigen Receptor T Cells
Number of Patients: 1
Published: December 10, 2022

The emerging therapeutic landscape of relapsed/refractory multiple myeloma.

Condition: Relapsed/Refractory Multiple Myeloma (RRMM)
Journal: Annals of hematology
Treatment Used: Teclistamab, Elranatamab, and Talquetamab
Published: December 03, 2022

Autologous and Allogeneic Stem Cell Transplantation as Salvage Treatment Options for Relapsed/Refractory Multiple Myeloma: A Single-center Experience over 20 Years.

Condition: Relapsed/Refractory Multiple Myeloma (MM)
Journal: Anticancer research
Treatment Used: Autologous Stem Cell Transplantation (auto-SCT)
Number of Patients: 75
Published: December 01, 2022

SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia.

Condition: Acute Myeloid Leukemia (AML)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Maintenance Therapy
Published: December 01, 2022

Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.

Condition: Relapsed/Refractory (R/R) Multiple Myeloma (MM)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Cobimetinib Alone and Plus Venetoclax with/without Atezolizumab
Number of Patients: 49
Published: November 30, 2022

The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.

Condition: Relapsed/Refractory Multiple Myeloma
Journal: European review for medical and pharmacological sciences
Treatment Used: Triplet Regimens Based on Pomalidomide and Dexamethasone
Number of Patients: 1889
Published: November 17, 2022

Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib.

Condition: Multiple Myeloma (MM)
Journal: Biomolecules
Treatment Used: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib
Number of Patients: 0
Published: November 11, 2022

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.

Condition: Relapsed/Refractory Multiple Myeloma (RRMM)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Ciltacabtagene Autoleucel
Number of Patients: 36
Published: November 10, 2022

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Condition: Multiple Myeloma
Journal: The Lancet. Haematology
Treatment Used: Isatuximab Added to Lenalidomide, Bortezomib, and Dexamethasone
Number of Patients: 660
Published: November 03, 2022

Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma.

Condition: Relapsed/Refractory Multiple Myeloma (RRMM)
Journal: Zhonghua yi xue za zhi
Treatment Used: Daratumumab
Number of Patients: 52
Published: November 01, 2022
Showing 1-12 of 648

Last Updated: 01/06/2023